Search results
Results from the WOW.Com Content Network
Related changes; Upload file; Special pages; ... Fanconi anemia group D2 protein is a protein that in humans is encoded by ... are an emerging therapeutic target in ...
Fanconi anemia, complementation group M, also known as FANCM is a human gene. [ 5 ] [ 6 ] It is an emerging target in cancer therapy, in particular cancers with specific genetic deficiencies. [ 7 ] [ 8 ]
Condition name ICD-10 coding number Diseases Database coding number Medical Subject Headings Iron-deficiency anemia: D50: 6947: Iron-deficiency anemia (or iron deficiency anaemia) is a common anemia that occurs when iron loss (often from intestinal bleeding or menses) occurs, and/or the dietary intake or absorption of iron is insufficient.
Another paper in Science by Pauling in 1968, [8] introduced and defined this view of molecular medicine that focuses on natural and nutritional substances used for treatment and prevention. Published research and progress was slow until the 1970s' "biological revolution" that introduced many new techniques and commercial applications.
The following outline is provided as an overview of and topical guide to clinical research: Clinical research is the aspect of biomedical research that addresses the assessment of new pharmaceutical and biological drugs, medical devices and vaccines in humans.
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS.
Interactive maps, databases and real-time graphics from The Huffington Post
It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen. [8] It is on the World Health Organization's List of Essential Medicines. [10] It was approved for medical use in the European Union in August 2007,